New hope for tough childhood cancer: boosting immune attack on neuroblastoma
NCT ID NCT07085338
Summary
This study is testing whether adding an experimental immune-boosting drug called N-803 to a standard chemoimmunotherapy regimen works better for treating neuroblastoma that has returned or is not responding to prior therapy. It will involve about 54 children and young adults under 30. The main goals are to see if the new combination is safe and if it leads to better tumor shrinkage and longer survival compared to the standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.